🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. innohep® 10.000 anti Xa IU/0,5mL PF.SYR. Ενέσιμο διάλυμα, innohep® 18.000 anti Xa IU/0,9mL PF.SYR. Ενέσιμο διάλυμα, innohep® 14.000 anti Xa IU/0,7mL PF.SYR. Ενέσιμο διάλυμα

    The George Institute

    Thromboprophylaxis in patients with advanced pancreatic cancer

    phase 3 small molecule active

    1 trial

  2. intensity-modulated radiation therapy

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 other active

    1 trial

  3. internal mammary nodal irradiation

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 3 other active

    1 trial

  4. mCapOX plus Cetuximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  5. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  6. mRNA-4157, Saline solution for Placebo to v940 (mrna-4157), KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. metformin hydrochloride

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  8. neoadjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  9. neratinib

    PUMA BIOTECHNOLOGY, INC.

    HER2+ Metastatic Breast Cancer (MBC)

    phase 3 small molecule completed

    1 trial

  10. nivolumab

    Bristol-Myers Squibb

    Breast Cancer

    phase 3 mab completed

    1 trial

  11. non-pegylated liposomal doxorubicin

    Teva Pharma GmbH

    Tubular Breast Cancer Stage II

    phase 3 small molecule completed

    1 trial

  12. normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab

    BeiGene

    Locally advanced, unresectable, or metastatic non small cell lung cancer

    phase 3 small molecule active

    1 trial

  13. novel stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 other active

    1 trial

  14. obrixtamig

    Boehringer Ingelheim

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  15. oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

    Takeda

    Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  16. paclitaxel/anthracycline

    The First People's Hospital of Lianyungang

    Primary Breast Cancer

    phase 3 small molecule active

    1 trial

  17. patients undergo cVATS segmentectomy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer Stage I

    phase 3 other active

    1 trial

  18. patients were assigned to receive TNT or iTNT management

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  19. pegcyte

    Biotech Pharmaceutical Co.,

    Breast Cancer Female

    phase 3 small molecule completed

    1 trial

  20. pegfilgrastim

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 mab active

    1 trial

  21. pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer

    phase 3 mab completed

    2 trials

  22. placebo

    Takeda

    Non-cancer Pain

    phase 3 small molecule terminated

    1 trial

  23. radiation therapy

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 3 other completed

    1 trial

  24. ramucirumab

    Eli Lilly and Company

    Gastric Cancer

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources